Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 9/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 9/20 | 0.47 |
| ▸ | HTR2B | P41595 | 7/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174395 | 0.94 | MLNR (0.50) | MLNRCYP2D6HTR2CHTR2BHTR2A | |
| SCHEMBL162032 | 0.90 | HTR2C (0.57) | MLNRCYP2D6HTR2CHTR2BHTR2A | |
| Bromide SCHEMBL174563 | 0.88 | HTR2C (0.55) | MLNRCYP2D6HTR2CHTR2BHTR2A | |
| Phosphoric Acid SCHEMBL174207 | 0.87 | HTR2C (0.47) | MLNRCYP2D6HTR2CHTR2BHTR2A | |
| Succinic Acid SCHEMBL174914 | 0.84 | HTR2C (0.45) | MLNRCYP2D6HTR2CHTR2BHTR2A | |
| Glycolic Acid SCHEMBL174349 | 0.84 | HTR2C (0.45) | MLNRCYP2D6HTR2CHTR2BHTR2A | |
| Malonic Acid SCHEMBL173339 | 0.84 | HTR2C (0.45) | MLNRCYP2D6HTR2CHTR2BHTR2A | |
| Nitric Acid SCHEMBL174071 | 0.84 | MLNR (0.47) | MLNRCYP2D6HTR2CHTR2BHTR2A | |
| Adipic Acid SCHEMBL173690 | 0.82 | HTR2C (0.42) | MLNRCYP2D6HTR2CHTR2BHTR2A | |
| Alpha-Ketoglutaric Acid SCHEMBL174620 | 0.79 | MLNR (0.43) | MLNRCYP2D6HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611427-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030927-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |